Concepedia

Author

Stephen G. Divers

The University of Texas MD Anderson Cancer Center

Also Known As

S. G. Divers, Stephen Divers, Stephen G. Divers

37

Publications

1.9K

Citations

10

H-Index

6

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterGuardant (United States)Princess Margaret Cancer CentreLouisiana State University Health Sciences Center ShreveportGenesis Medical Center
SG

About

Stephen G. Divers is an author at The University of Texas MD Anderson Cancer Center specializing in cancer therapeutics, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

19

2

Pharmacology

1

1

19

3

Cancer Therapeutics

1

1

19

4

Breast Cancer

1

1

19

5

Oncology

1

1

19

Stephen G. Divers

×

8

Publications

1.7K

Citations

8

H-Index

YearCitations

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill,

PLoS ONE

2015

708

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Natasha B. Leighl, Ray D. Page, Victoria M. Raymond,

Clinical Cancer Research

2019

584

Informed Consent for Clinical Trials: a Comparative Study of Standard Versus Simplified Forms

Terry C. Davis, Hans J. Berkel, Randall F. Holcombe,

JNCI Journal of the National Cancer Institute

1998

283

Quantitation of CD62, soluble CD62, and lysosome‐associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates

Stephen G. Divers, K. Kannan, R. Malcolm Stewart,

Transfusion

1995

54

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer

Ray D. Page, Leylah Drusbosky, Hiba I. Dada,

Clinical Lung Cancer

2021

40

Cell surface expression of lysosome‐associated membrane protein‐2 (lamp2) and CD63 as markers of<i>in vivo</i>platelet activation in malignancy

K. Kannan, Stephen G. Divers, A. Lurie,

European Journal Of Haematology

1995

28

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

Phuong K. Morrow, Stephen G. Divers, Louise Provencher,

Breast Cancer Research and Treatment

2010

19

Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non–Small-Cell Lung Cancer

Stephen G. Divers, Sharon A. Spencer, Delicia Carey,

Journal of Clinical Oncology

2005

15

Page 1